CN116251062A - Preparation method and application of bacterial membrane-liposome drug-loading system - Google Patents
Preparation method and application of bacterial membrane-liposome drug-loading system Download PDFInfo
- Publication number
- CN116251062A CN116251062A CN202310337764.9A CN202310337764A CN116251062A CN 116251062 A CN116251062 A CN 116251062A CN 202310337764 A CN202310337764 A CN 202310337764A CN 116251062 A CN116251062 A CN 116251062A
- Authority
- CN
- China
- Prior art keywords
- bacterial membrane
- liposome
- drug delivery
- delivery system
- liposome drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 77
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000011068 loading method Methods 0.000 title abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 40
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 239000012528 membrane Substances 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 229940109262 curcumin Drugs 0.000 claims description 55
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims description 50
- 238000012377 drug delivery Methods 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 9
- 235000012754 curcumin Nutrition 0.000 claims description 9
- 239000004148 curcumin Substances 0.000 claims description 9
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 9
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 102000016943 Muramidase Human genes 0.000 claims description 5
- 108010014251 Muramidase Proteins 0.000 claims description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 5
- 229960000274 lysozyme Drugs 0.000 claims description 5
- 235000010335 lysozyme Nutrition 0.000 claims description 5
- 239000004325 lysozyme Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000012880 LB liquid culture medium Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000000409 membrane extraction Methods 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 28
- 210000000440 neutrophil Anatomy 0.000 abstract description 21
- 238000001959 radiotherapy Methods 0.000 abstract description 12
- 230000008685 targeting Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 230000005975 antitumor immune response Effects 0.000 abstract description 6
- 150000003904 phospholipids Chemical class 0.000 abstract description 6
- 230000001363 autoimmune Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 208000005017 glioblastoma Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000011065 in-situ storage Methods 0.000 description 9
- 239000010408 film Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000024055 brain glioblastoma Diseases 0.000 description 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940063519 doxorubicin hydrochloride liposome Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method and application of a bacterial membrane-liposome drug-loading system. According to the invention, the bacterial membrane-liposome drug-carrying system is prepared by blending the bacterial membrane and the phospholipid, so that the riding capacity of neutrophils is enhanced, and then the drug is targeted and delivered to tumor tissues, especially tumor tissues after radiotherapy, and meanwhile, the anti-tumor immune response of an organism is stimulated, so that the treatment effect is improved, and the problems of insufficient tumor targeting and insufficient autoimmune stimulation efficiency of the liposome drug-carrying system are solved.
Description
Technical Field
The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of a bacterial membrane-liposome drug delivery system.
Background
Tumors have been threatening to human health, and treatments aimed at tumors mainly include surgery, radiation therapy, chemo-drug therapy, and immunotherapy. The nano medicine carrying system can improve the bioavailability of the chemotherapeutic medicine and the targeting of tumor tissues, and is widely applied to preclinical research and clinical practice. The liposome drug delivery system has a structure similar to that of a biological membrane, hydrophilic drugs can be loaded in the inner cavity of the liposome drug delivery system, and hydrophobic drugs can be loaded between the phospholipid bilayer layers. As a drug carrier, the liposome has the advantages of wide drug carrying range, slow release, easy modification, high safety, capability of reducing adverse reaction of the drug, improvement of the stability of the drug and the like. The liposome products currently on the market in China mainly comprise taxol liposome injection, amphotericin B liposome for injection and doxorubicin hydrochloride liposome injection.
Although the liposome drug delivery system plays an important role in clinical anti-tumor chemotherapy, the liposome drug delivery system can be further improved in the aspects of tumor targeting and the anti-tumor efficacy of the carrier. The liposome is used as a nano carrier of a chemotherapeutic drug, and can realize tumor-specific treatment by passively targeting to tumor tissues through the high permeability and retention (Enhanced Permeability and Retention, EPR) effect of solid tumors. However, numerous research reports and clinical practices indicate that the EPR effect of nanoparticles is not prominent, thus increasing the active targeting ability of liposomes to tumors is particularly important. The main mode adopted at present is to use saccharides and derivatives thereof, antibodies, polymers, peptides and the like to modify liposome so as to improve the active targeting of the liposome to different diseases. In the modification process, the problems of low connection efficiency, complicated separation and purification steps, uncertainty of the target performance improvement degree and the like exist. On the other hand, with the development of nano technology, a part of nano particles applied to tumor treatment can be used as a chemotherapeutic drug carrier, and can safely and effectively sensitize various tumor treatment modes (such as radiation treatment, immunotherapy and the like) so as to improve the anti-tumor curative effect. The liposome has simple components, does not have any anti-tumor efficacy when not carrying medicine, and can not excite the anti-tumor immune response of the organism.
The inside of the tumor tissue has inflammation, and after surgery, radiotherapy, photothermal treatment, etc., the inflammation inside the tumor is further amplified, a large amount of chemokines are expressed, and neutrophils in peripheral blood are recruited. Thus, the drug delivery system can target tumor tissue, particularly tumor tissue following surgery or radiation therapy, with neutrophils. In recent years, a part of anaerobic or facultative anaerobic bacteria have been used in research on tumor treatment because they can specifically proliferate in tumor hypoxia microenvironment and induce systemic antitumor immune response in the body. The bacillus calmette-guerin is a typical representative, is an attenuated bovine type tubercle bacillus, can promote the activity of macrophages, activate T lymphocytes and strengthen the immunity of the organism against tumor cells. The bacterial outer membrane collected from the bacteria is structurally similar to liposomes and can target tumors with neutrophils and stimulate anti-tumor immunotherapeutic responses. However, the bacterial outer membrane has the defects of complex collection process, complicated steps, small extraction amount, difficult drug loading as a drug carrier and the like. The bacterial membrane can be obtained in large quantity by dissolving bacteria, also has a structure of a biological membrane, and can trigger the anti-tumor immunity of organisms. Meanwhile, a part of biological film is used for being mixed with phospholipid to construct a liposome drug carrying system doped with the biological film, so that various performances of the liposome are improved. Therefore, the bacterial membrane and the phospholipid are blended, so that a bacterial membrane-liposome drug-loading system capable of riding neutrophils is very likely to be constructed, and the tumor targeting performance and the immunostimulation efficacy of the liposome are improved.
Disclosure of Invention
The invention aims to prepare a bacterial membrane-liposome drug-carrying system by blending bacterial membranes with phospholipids, enhance the riding capacity on neutrophils, further target and deliver drugs to tumor tissues, especially tumor tissues after radiotherapy, and simultaneously excite anti-tumor immune response of organisms, so as to improve the treatment effect and solve the problems of insufficient tumor targeting and insufficient autoimmune stimulation efficiency of the liposome drug-carrying system.
In order to achieve the above purpose, the present invention adopts the following technical effects:
a bacterial membrane-liposome medicine carrying system is prepared from dipalmitoyl phosphatidylcholine and DSPE-PEG 5000 Cholesterol and bacterial membrane, dipalmitoyl phosphatidylcholine, DSPE-PEG 5000 The mass ratio of cholesterol to bacterial membrane is 3:2:1:1.
further, the bacterial membrane is made of VNP20009 strain.
Further, the bacterial membrane-liposome drug delivery system is coated with curcumin and 1-methyl-D-tryptophan.
The preparation method of the bacterial membrane-liposome drug delivery system comprises the following steps:
Further, 2g of the bacteria were dissolved in 40mL of 15mg/mL lysozyme in 20mmol/L Tris HCl buffer pH8.0 with SDS at 400mg in step 1; the volume ratio of the chloroform to the methanol to the water is 30:15:1.
The bacterial membrane-liposome drug-loading system is applied to the preparation of tumor therapeutic drugs.
The beneficial effects are that:
1. the bacterial membrane-liposome drug-loading system has the advantages of simple synthesis method, uniform size and good dispersibility, and can simultaneously load hydrophilic and hydrophobic drugs.
2. Compared with liposome, the bacterial membrane-liposome drug-loading system can be more ingested by neutrophils, further targets tumor tissues after radiotherapy, and releases drugs in an inflammatory environment.
3. The bacterial membrane-liposome drug-loading system can activate the anti-tumor immune response of organisms and enhance the curative effect of radiotherapy on glioblastoma.
Drawings
FIG. 1 is a schematic diagram of the bacterial membrane-liposome drug delivery system (B-Lipo/1-MT & Cur) of the present invention.
FIG. 2 is a transmission electron microscope image of B-Lipo/1-MT & Cur in example 1.
FIG. 3 shows the co-localization results of B-Lipo/1-MT & Cur or bacterial membrane and liposome mixtures taken up by cells in example 1.
FIG. 4 shows the UV-visible absorption spectra of 1-MT, cur, two drug loaded liposomes (Lipo/1-MT & Cur) and B-Lipo/1-MT & Cur of example 1.
FIG. 5 shows the release of B-Lipo/1-MT & Cur from 1-MT and Cur at different pH values in example 1.
FIG. 6 shows the mean fluorescence intensity results of neutrophils in mouse blood and tumors after intravenous injection of fluorescently labeled liposomes or bacterial membrane-liposomes as in example 1.
FIG. 7 shows the results of bioluminescence and fluorescence imaging of brains of mice bearing luc-stably transformed glioblastoma from different treatment groups collected 24 hours after intravenous administration in example 1.
FIG. 8 is a confocal image of GL261 tumor cells after removing the medium containing neutrophils after incubating the neutrophils having ingested B-Lipo/1-MT & Cur with GL261 tumor cells under normal or inflammatory conditions in example 1.
FIG. 9 is cytotoxicity of the infiltrate in glioblastoma in situ the fourth day after treatment in example 1T-cells (CD 3) + CD8 + ) In CD3 + Ratio in cells.
FIG. 10 shows regulatory T cells (CD 3) in glioblastoma in situ the fourth day after treatment in example 1 + CD4 + Foxp3 + ) In CD3 + CD4 + Ratio in T cells.
FIG. 11 is a graph showing M1 type macrophages (CD 11 b) in glioblastoma cells in situ the fourth day after treatment in example 1 + F4/80 + CD86 + ) At CD11b + F4/80 + Ratio in cells.
FIG. 12 shows M2 type macrophages (CD 11 b) in glioblastoma in situ the fourth day after treatment in example 1 + F4/80 + CD206 + ) At CD11b + F4/80 + Ratio in cells.
FIG. 13 is a plot of survival of mice bearing glioblastoma in situ in different treatment groups in example 1.
Detailed Description
The invention will now be described in further detail with reference to the drawings and specific examples, which should not be construed as limiting the invention. Modifications and substitutions to methods, procedures, or conditions of the present invention without departing from the spirit and nature of the invention are intended to be within the scope of the present invention. The experimental procedures and reagents not shown in the formulation of the examples were all in accordance with the conventional conditions in the art.
The VNP20009 strain used in the present invention was purchased from American type culture Collection (American Type Culture Collection, ATCC).
Example 1
The embodiment constructs a bacterial membrane-liposome drug-carrying system (B-Lipo), and encapsulates a hydrophilic drug of 1-Methyl-tryptophan (1-Methyl-D-trytophan, 1-MT) and a hydrophobic drug of Curcumin (Curcumin, cur) to obtain the B-Lipo/1-MT & Cur, which is applied to targeted drug delivery and combined radiation-immunotherapy of in-situ brain glioblastoma.
The synthesis steps are as follows:
1. extraction of bacterial film:
VNP20009 strainBacteria were obtained by passaging using LB (Luria-Bertani) liquid medium, and after passage to 3 passages, centrifuging at 4500rpm for 20 min. 2g of bacteria were dissolved in 40mL Tris HCl buffer (20 mmol/L, pH=8.0) containing lysozyme (15 mg/mL), incubated at 37℃for 3h with shaking, 400mg SDS was added, treated with a cytobreaker for 10min, and lyophilized. Chloroform, methanol and water (30:15:1, v/v/v) were then added, treated with a cell disrupter for 10min, incubated at 37℃for 1h, and 0.45 μm Millipore HVLP was usedThe membrane was filtered, the liquid was removed using a rotary evaporator and dried to obtain a bacterial membrane.
2. Synthesis of B-Lipo/1-MT & Cur:
synthesized using a thin film dispersion method: according to the mass ratio of 3:2:1:1 weighing 9mg DPPC, 6mg DSPE-PEG 5000 3mg of cholesterol and 3mg of bacterial film, 1mg of liposoluble drug curcumin (Cur) was added, dissolved in 2mL of chloroform, and the liquid was removed by a rotary evaporator to form a film on the bottle wall. 1mL of 1-MT aqueous solution (2 mg/mL) was then added, and the solution was completely dissolved by sonication for 20min, followed by stirring at 45℃for 2h, and liposomes of appropriate size were extruded through 200nm and 400nm polycarbonate membranes using a liposome extruder. Washing with deionized water for 3 times with ultrafiltration tube of 100KD to remove free drug to obtain B-Lipo/1-MT&Cur。
The synthesis step of simultaneously preparing a liposome drug carrying system (Lipo/1-MT & Cur) loaded with 1-MT and Cur comprises the following steps: on the basis of the step of synthesizing B-Lipo/1-MT & Cur, the addition of 3mg of bacterial membrane was subtracted, the remaining steps remaining the same.
The prepared bacterial membrane-liposome drug-loading system for encapsulating the drug is shown in figure 1, and the nano particles have a uniform spherical structure and have a size of about 100nm as shown in figure 2 when observed by a transmission electron microscope.
To demonstrate that the above synthetic method allowed successful fusion of bacterial membrane and liposome, bacterial Membrane (BM) was stained with FITC fluorescence and liposome stained with DID fluorescence to prepare B-Lipo. After co-incubation of B-Lipo with cells, it was observed by confocal fluorescence microscopy. As shown in FIG. 3, the simple mixing of the liposome and bacterial membrane (BM+Lipo) resulted in substantially non-coincident fluorescence of both, while the two fluorescence of B-Lipo fused together intracellularly, demonstrating successful fusion of the bacterial membrane and liposome.
The drug carrying capacity and drug releasing capacity of the bacterial membrane-liposome drug carrying system are shown in fig. 4 and 5: the ultraviolet absorption spectrum shows that the drug carrying system successfully carries the drugs 1-MT and Cur, and the encapsulation rates are respectively as follows: 1-MT: 35.25+ -0.01%; cur:47.23 +/-0.01%. After that, the ability of the drug delivery system to release the drug was simulated in vitro, 1mL of B-Lipo/1-MT & Cur aqueous solution was placed in a dialysis bag, and placed in 15mL of serum bottles containing phosphate buffers of different pH (ph= 5.6,6.5,7.4) and stirred, thereby simulating the release of the material at different pH, and the content of 1-MT and Cur was measured using an ultraviolet spectrophotometer. The results show that under different pH environments, the slow release of Cur and 1-MT can be realized by the B-Lipo/1-MT & Cur.
To verify whether bacterial membrane-lipids can enter tumor sites, especially tumor tissue following radiotherapy, by riding neutrophils. DID (fluorescent dye) labeled liposomes or bacterial membrane-liposomes with a maximum excitation wavelength of 644nm and a maximum emission wavelength of 665nm were first prepared. The specific synthesis steps are as follows: 9mg DPPC, 6mg DSPE-PEG are weighed 5000 3mg of cholesterol (mass ratio 3:2:1) was dissolved in 2mL of chloroform, 5. Mu.L of DID was added, and the liquid was removed by a rotary evaporator to form a film on the bottle wall. 1mL of water was added and sonicated for 20min to dissolve completely, then stirred at 45℃for 2h, and liposomes of appropriate size were extruded through 200nm and 400nm polycarbonate membranes using a liposome extruder. The free material was removed by washing 3 times with deionized water using a 100KD ultrafiltration tube to give DID-labeled liposomes (DID-Lipo). To obtain DID-labeled bacterial membrane-liposome (DID-B-Lipo), 3mg of bacterial membrane was added to blend with other phospholipids in the first step of the synthesis of DID-Lipo described above, and the remaining steps were kept consistent. GL261 in situ glioblastoma bearing mice were divided into two groups, and DID-Lipo and DID-B-Lipo (DID: about 5 μg/each mouse, lipo: about 90mg/Kg, bacterial membrane: about 15 mg/Kg) of the same DID fluorescence intensity were injected via the tail vein, respectively, and after 4 hours, the blood and tumor of the mice were taken, and neutrophils were extracted and isolated. Analysis of small using flow cytometryFluorescence intensity of DID in neutrophils in murine blood and tumor. As shown in fig. 6, the results showed that liposomes containing bacterial membranes showed better affinity to neutrophils in both blood and tumor compared to normal liposomes.
To further verify the inflammation targeting effect, further observations were made using the small animal imaging system (IVIS). Mice with glioblastoma in situ were divided into 5 groups: g1: lipo/1-MT & Cur; and G2: X-ray+lipo/1-MT & Cur; and G3: B-Lipo/1-MT & Cur; and G4: X-ray+B-Lipo/1-MT & Cur+anti-Gr-1; and G5: X-ray+B-Lipo/1-MT & Cur intravenous injection time of the pharmaceutical preparations (including Lipo/1-MT & Cur and B-Lipo/1-MT & Cur) in each group was within one hour after the irradiation of X-rays (irradiation dose: 5 Gy). The intravenous time of anti-Gr-1 was 50 μg/mouse after X-ray irradiation and before the injection of the pharmaceutical formulation. The DID,1-MT and Cur content in the pharmaceutical preparation were the same, and were 5. Mu.g/DID, 13.19mg/kg 1-MT and 9.06mg/kg Cur, respectively, per mouse. After 24 hours, the mouse brains were collected for bioluminescence imaging and DID fluorescence imaging and quantitative analysis. As shown in fig. 7, the inflammatory effect is further enhanced when the tumor site is treated with X-rays, after which the bacterial membrane-liposome drug delivery system is injected into the tail vein, and its targeting effect is the best. After the antibody Gr-1 of neutrophils was injected, it was consumed on neutrophils in vivo, and drug injection was performed again, it was found that its targeting was weakened, indicating that the increase in targeting was neutrophil dependent.
In order to examine whether neutrophils can release bacterial membrane-liposome drug-loading system under inflammatory environment and are taken up by tumor cells, neutrophils loaded with B-Lipo/1-MT & Cur were incubated with GL261 tumor cells under inflammatory environment (medium containing phorbol ester (phorbol myristate acetate, PMA: medium: 1:250)) and normal environment (normal medium), and observed by confocal microscopy, as shown in FIG. 8, the results showed that more Cur was taken up by tumor cells under inflammatory environment, indicating that better release of B-Lipo/1-MT & Cur and drug loaded by neutrophils was taken up by tumor cells under inflammatory environment. Therefore, the bacterial membrane-liposome drug-carrying system can ride neutrophils and release drugs to tumor tissues under the induction of inflammatory factors, so that a better drug delivery effect is achieved.
An immunoassay of the tumor treatment was then performed in combination with B-Lipo/1-MT & Cur. The following 4 groups were divided: g1: PBS; and G2: x-rays; and G3: X-ray+lipo/1-MT & Cur; and G4: X-ray+B-Lipo/1-MT & Cur, intravenous Lipo/1-MT & Cur and B-Lipo/1-MT & Cur,1-MT respectively within 1 hour after X-ray irradiation: 13.19mg/kg; cur:9.06mg/kg; dose of X-rays: 5Gy. Immune cells were analyzed by flow cytometry on day 4. As shown in fig. 9-12, it was found that the ratio of cytotoxic T cells in tumor was increased, the ratio of regulatory T cells was decreased, the ratio of M1 type macrophages was increased, and the ratio of M2 type macrophages was decreased after the radiotherapy was combined with the bacterial membrane-liposome drug delivery system, compared with the combined simple liposome drug delivery system, indicating that the bacterial membrane was able to activate the antitumor immune response of the body.
Finally, experiments for treating in-situ glioblastoma are carried out, and the advantages of the drug carrying system are further verified. Mice were grouped as G1: PBS; and G2: x-rays; and G3: X-ray+lipo/1-MT & Cur; and G4: X-ray+B-Lipo/1-MT & Cur. Intravenous injection of Lipo/1-MT & Cur and B-Lipo/1-MT & Cur,1-MT, respectively, within 1 hour after X-ray irradiation: 13.19mg/kg; cur:9.06mg/kg; dose of X-rays: 5Gy. Mice on the day of X-ray exposure, mice in each group began to record body weight and death. As shown in fig. 13, the survival time of mice can be prolonged significantly by combining radiotherapy with a bacterial membrane-liposome drug-loading system, which is obviously better than that of the radiotherapy with a liposome drug-loading system. This result is mainly because bacterial membrane-liposomes can better target tumor tissue after radiotherapy and synergistically activate the body's anti-tumor immune system compared to normal liposomes.
Claims (6)
1. A bacterial membrane-liposome drug delivery system, characterized by: from dipalmitoyl phosphatidylcholine, DSPE-PEG 5000 Cholesterol and bacterial membrane, dipalmitoyl phosphatidylcholine, DSPE-PEG 5000 The mass ratio of cholesterol to bacterial membrane is 3:2:1:1.
2. the bacterial membrane-liposome drug delivery system of claim 1, wherein: the bacterial membrane is made of VNP20009 strain.
3. The bacterial membrane-liposome drug delivery system of claim 1, wherein: the bacterial membrane-liposome drug delivery system comprises curcumin and 1-methyl-D-tryptophan.
4. The method for preparing the bacterial membrane-liposome drug delivery system of claim 1, wherein the method comprises the steps of: the method comprises the following steps:
step 1, bacterial membrane extraction, namely, carrying out passage on a VNP20009 strain by using an LB liquid culture medium, carrying out centrifugation after passage for 3 generations to obtain bacteria, dissolving the bacteria in a Tris HCl buffer solution containing lysozyme, carrying out shaking incubation, adding SDS, treating by using a cell disruption instrument, adding a mixed solution of chloroform, methanol and water after freeze-drying, treating by using the cell disruption instrument, incubating, filtering, and drying filtrate to obtain the bacterial membrane;
step 2, dipalmitoyl phosphatidylcholine and DSPE-PEG 5000 Cholesterol and bacterial membrane freeze-dried powder according to the mass ratio of 3:2:1:1, adding fat-soluble medicine curcumin, dissolving the medicine curcumin in chloroform, removing volatile organic reagent by using a rotary evaporator to form a film on the bottle wall, then adding 1-methyl-D-tryptophan aqueous solution, completely dissolving the film by ultrasonic, stirring and mixing, and preparing liposome by using a liposome extruder, thereby obtaining the bacterial membrane-liposome medicine carrying system.
5. The method of manufacturing according to claim 4, wherein: in step 1, 2g of bacteria were dissolved in 40mL of 15mg/mL lysozyme in 20mmol/L Tris HCl buffer pH8.0, with SDS being used in an amount of 400mg; the volume ratio of the chloroform to the methanol to the water is 30:15:1.
6. Use of the bacterial membrane-liposome drug delivery system of claim 1 for the preparation of a medicament for the treatment of tumors.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310337764.9A CN116251062A (en) | 2023-03-31 | 2023-03-31 | Preparation method and application of bacterial membrane-liposome drug-loading system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310337764.9A CN116251062A (en) | 2023-03-31 | 2023-03-31 | Preparation method and application of bacterial membrane-liposome drug-loading system |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116251062A true CN116251062A (en) | 2023-06-13 |
Family
ID=86686319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310337764.9A Pending CN116251062A (en) | 2023-03-31 | 2023-03-31 | Preparation method and application of bacterial membrane-liposome drug-loading system |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116251062A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117137884A (en) * | 2023-08-17 | 2023-12-01 | 苏州大学 | Nanometer medicinal composition based on bacterial cell membrane, and preparation method and application thereof |
-
2023
- 2023-03-31 CN CN202310337764.9A patent/CN116251062A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117137884A (en) * | 2023-08-17 | 2023-12-01 | 苏州大学 | Nanometer medicinal composition based on bacterial cell membrane, and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111265533B (en) | Preparation method of core-shell nano-particles based on lipid membrane and metal organic framework | |
Liu et al. | Challenges in cell membrane-camouflaged drug delivery systems: development strategies and future prospects | |
Chen et al. | Living leukocyte‐based drug delivery systems | |
CN106137967B (en) | Target the preparation and application of the dual modified liposome drug delivery system of glioma | |
Yao et al. | Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy | |
CN113384530B (en) | Polysaccharide core Nanocells and preparation method and application thereof | |
CN112716915A (en) | Bionic nano-carrier and application thereof in preparing medicament for treating brain glioma | |
CN114259477B (en) | Nano delivery system capable of promoting penetration, relieving tumor hypoxia and targeting tumor cells, and preparation method and application thereof | |
Dai et al. | Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy | |
Wu et al. | Recent advancement of bioinspired nanomaterials and their applications: A review | |
CN116251062A (en) | Preparation method and application of bacterial membrane-liposome drug-loading system | |
CN112546062A (en) | Perfluorocarbon silicon plastid and preparation method and application thereof | |
Hu et al. | The application of nanoparticles in immunotherapy for hepatocellular carcinoma | |
CN110812493A (en) | Preparation method and application of self-contained nano generator pharmaceutical composition based on probiotic spores | |
JP6238366B2 (en) | Lipid membrane structure encapsulating bacterial cell component dispersible in nonpolar solvent and method for producing the same | |
CN102085189B (en) | Docetaxel liposome sterile lyophilized preparation and preparation method thereof | |
CN116650673A (en) | Cell membrane coated medicine fat granule and its preparation method and application | |
CN108721643B (en) | pH sensitive liposome for immune chemotherapy | |
CN107823652B (en) | Long-circulation self-assembly composite nano preparation, preparation method and application thereof | |
KR102525384B1 (en) | Manufacturing method for extracellular vesicles containing dual drugs | |
CN114191539A (en) | Exosome nano particle for composite co-transport of small molecule nucleic acid and active protein, and preparation method and application thereof | |
CN112603890A (en) | Levatinib liposome and pharmaceutical composition thereof, preparation method thereof and prescription process optimization method | |
CN116077460A (en) | Ganoderan nanoparticle loaded with chemotherapeutic drugs | |
Xie et al. | A new track for antibacterial treatment: progress and challenges of using cytomembrane-based vesicles to combat bacteria | |
CN114748424A (en) | Liposome drug delivery system and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |